4 New Patient Organizations Join the CATALIS Network
The CATALIS Network keeps growing. Bladder Cancer Canada, and the Canadian Liver Foundation, and Fighting Blindness Canada have joined 3 patient partners and more than 30 patient organizations. Together, they represent the patient’s voice and contribute to CATALIS’ mission, which is to optimize clinical research in Quebec, in order to accelerate the development of innovative patient care for everyone’s benefit.
“We are delighted to work with CATALIS, a leader in Quebec’s clinical research ecosystem. Its mission aligns perfectly with our commitment to building patient capacity through education. My job allows me to talk to people with bladder cancer on a daily basis. Listening to their inspiring and difficult, sometimes overwhelming stories makes me realize how crucial it is that patients and caregivers have easy access to the resources and information they need to understand a diagnosis and can obtain up-to-date information about clinical trials.” – Michelle Colero, Executive Director, Bladder Cancer Canada
“The Canadian Liver Foundation (CLF) is a leader in the liver health sphere – driving new discoveries, improving public awareness, and supporting the 1 in 4 Canadians affected by liver disease. We welcome the opportunity to assist Quebec liver patients, caregivers, and healthcare professionals in their search for clinical trials. Research brings hope to those facing liver disease, and clinical trials can improve health outcomes. They also allow patients to access top care and the latest health innovations while advancing research in Canada. The CLF is excited to be working with CATALIS on this important project, as it aligns with our patient-centred approach to education, support, and research.” – Jennifer Nebesky, President & CEO, Canadian Liver Foundation
“Fighting Blindness Canada has invested in and advocated for increased clinical trial capacity in Quebec and across Canada. Clinical trials play a crucial role in the research ecosystem, offering hope, better care, and innovative treatments for patients with vision loss caused by eye diseases. We are pleased to partner with CATALIS and its Personalized Support Service to help our Quebec members learn more about and access new clinical trials.” – Jennifer Jones, President and CEO, Fighting Blindness Canada
“Pancreatic cancer has a survival rate of just 10% so taking on the urgent challenge of this disease requires inventive solutions. At Pancreatic Cancer Canada, we believe that staying at the forefront of novel approaches to treatments and improved patient outcomes is how we will get closer to the next breakthrough for this disease. That’s why we are proud to partner with CATALIS in its mission to optimize the clinical research environment to accelerate the development of innovative care for the benefit of patients in Quebec and beyond.” – Michelle Capobianco, CEO, Pancreatic Cancer Canada
